Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Septerna, Inc. is a clinical-stage biotechnology company focused on the discovery and development of oral small‑molecule medicines targeting G protein‑coupled receptors (GPCRs), a large and historically challenging class of drug targets. The company operates within the biopharmaceutical and life sciences industries, with a strategic emphasis on diseases where GPCR biology is well‑validated but existing therapies are limited, injectable, or suboptimal. Septerna’s approach centers on designing molecules that selectively modulate GPCRs in ways that aim to improve efficacy, safety, and patient convenience.
The company’s primary value drivers are its proprietary GPCR discovery platform and a pipeline of early‑stage clinical and preclinical programs, including candidates in endocrinology, metabolic disease, and immunology. Septerna was founded in 2020 by former leaders of the GPCR-focused biotechnology company Sosei Heptares, leveraging decades of structure‑based drug design experience. The company completed an initial public offering in 2023 and is listed on the Nasdaq under the ticker SEPN, positioning itself as a pure‑play GPCR therapeutics innovator.
Business Operations
Septerna’s operations are organized around a single integrated business model encompassing drug discovery, preclinical development, and early clinical development. Revenue generation to date has primarily consisted of collaboration and partnership payments, with no approved commercial products as of the latest publicly available filings. The company’s internal pipeline includes multiple GPCR programs, some wholly owned and others partnered, designed to advance into human clinical trials.
The company controls a proprietary GPCR structure‑based discovery engine that integrates protein engineering, computational chemistry, and medicinal chemistry. Septerna operates primarily in the United States, with research and development activities supported by internal teams and external contract research organizations. Data inconclusive based on available public sources regarding the existence of consolidated subsidiaries or joint ventures beyond standard research collaborations.
Strategic Position & Investments
Strategically, Septerna aims to build a diversified portfolio of best‑in‑class and first‑in‑class oral GPCR therapeutics, while selectively partnering programs to offset development risk and fund operations. Growth initiatives include advancing lead assets into clinical proof‑of‑concept, expanding the GPCR target universe addressable by small molecules, and leveraging its platform for additional discovery collaborations.
The company has entered into research and development partnerships with established pharmaceutical companies to co‑develop selected programs, receiving upfront payments, milestone potential, and future royalties. Septerna’s investment focus remains internal, centered on R&D spending rather than external equity investments or acquisitions. Data inconclusive based on available public sources regarding completed acquisitions of other companies since inception.
Geographic Footprint
Septerna is headquartered in South San Francisco, California, a major global biotechnology hub. Its core operations, including executive leadership and research management, are based in the United States, with laboratory and development activities primarily concentrated in North America.
While the company does not maintain large-scale international facilities, its research and development activities have a global reach through partnerships, licensing arrangements, and the use of international contract research organizations. The company’s investor base and strategic collaborators include entities across North America and Europe, reflecting an international operational influence despite a predominantly U.S.-based physical footprint.
Leadership & Governance
Septerna was founded by industry veterans with deep expertise in GPCR biology and structure‑based drug design. The leadership team emphasizes scientific rigor, capital discipline, and strategic partnerships as core elements of its governance philosophy, with a stated focus on long‑term value creation through differentiated science.
Key executives include:
- Jeffrey M. Finer – Chief Executive Officer
- Daniel T. O’Connell – Chief Financial Officer
- Michael L. Brown, Ph.D. – Chief Scientific Officer
- Karen L. Lewis, M.D. – Chief Medical Officer
The company is governed by a board of directors comprised of biotechnology executives and investors with experience in drug development, public company governance, and capital markets, consistent with its status as a Nasdaq‑listed clinical‑stage biotechnology company.